Disease · MONDO_0011849
Trials232
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
1 to 20 of 232
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01623752 | Prospective Evaluation of the Radiographic Efficacy of Enbrel | 1,821 | 2019-08-16 | Rheumatoid Arthritis, Psoriasis Arthritis | ETANERCEPT | Its record names the disease | ClinicalTrials.gov | |
| NCT03104400 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Phase 3 | 1,705 | 2022-01-25 | Psoriatic Arthritis | UPADACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01313858 | A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554) | 1,613 | 2016-11-01 | Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing | GOLIMUMAB, METHOTREXATE | Its record names the disease | ClinicalTrials.gov | |
| NCT02486302 | A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis. | 1,534 | 2019-06-24 | Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Plaque Psoriasis | ETANERCEPT | Its record names the disease | ClinicalTrials.gov | |
| NCT00293722 | Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists | 1,308 | 2014-02-26 | Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous | ETANERCEPT | Its record names the disease | ClinicalTrials.gov | |
| NCT00760669 | An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants | 1,061 | 2013-08-12 | Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis, Arthritis, Psoriatic | INFLIXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04882098 | A Study of Guselkumab in Participants With Active Psoriatic Arthritis | Phase 3 | 1,054 | 2026-02-04 | Arthritis, Psoriatic | GUSELKUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02404350 | Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis | Phase 3 | 997 | 2019-06-28 | Psoriatic Arthritis | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03675308 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | Phase 3 | 964 | 2022-02-24 | Psoriatic Arthritis | RISANKIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02745080 | Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis | Phase 3 | 853 | 2021-01-27 | Psoriatic Arthritis | ADALIMUMAB, SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03895203 | A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | Phase 3 | 852 | 2024-10-23 | Psoriatic Arthritis | BIMEKIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02376790 | Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis | Phase 3 | 851 | 2019-02-22 | Psoriatic Arthritis | ETANERCEPT, METHOTREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT00245960 | Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis | Phase 4 | 752 | 2009-05-27 | Psoriatic Arthritis | ETANERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT03158285 | A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis | Phase 3 | 741 | 2020-11-05 | Arthritis, Psoriatic | GUSELKUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00574249 | Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment | Phase 3 | 730 | 2010-01-18 | Chronic Plaque Psoriasis | ADALIMUMAB, BETAMETHASONE, CALCIPOTRIENE | Its record names the disease | ClinicalTrials.gov |
| NCT04908189 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment | Phase 3 | 729 | 2025-04-13 | Psoriatic Arthritis | APREMILAST, DEUCRAVACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01976364 | Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis | Phase 3 | 686 | 2020-05-21 | Arthritis, Psoriatic | TOFACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04908202 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs | Phase 3 | 670 | 2025-10-24 | Psoriatic Arthritis | DEUCRAVACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03104374 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug | Phase 3 | 642 | 2022-01-25 | Psoriatic Arthritis | UPADACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01009086 | A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis | Phase 3 | 615 | 2014-03-13 | Arthritis, Psoriatic | USTEKINUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011849/trials